The Israel-based biotech firm Stereo Biotechs has conducted a limited-scale clinical study on the impact of a steroid-cannabidiol (CBD) therapy on admitted COVID-19 patients at Rabin Medical Center’s Golda Hasharon Campus in Petach Tikvah. Steroid therapy for hospitalized patients typically is the first or second phase of therapy.
CBD increases the beneficial impact of steroid therapy and prevents the virus-affected bio-mechanism, “the firm said in a press release detailing the clinical trial.”The initial analysis would determine the tolerability, protection and effectiveness of the CBD care for patients with COVID-19 viruses in hospital.”
Ten patients would be in the clinical study; a follow-up phase of the same duration will be the procedure for a few weeks. The organization plans to grow to a multi-centre medical trial with a further 40 hospitalized COVID-19 patients, under FDA standards and regulations for clinical trials, following the success of the study.
We measure that our CBD-based therapy can boost the current medication of those sick people who are experiencing life-threatening conditions, ”said Stereo Biotechs Founder and CEO David Bassa. Hospitalized COVID-19 sufferers are often being handled with steroids, and our analysis is designed to indicate the advantage of a paired solution with steroid therapies, “he continued.
We are optimistic that this analysis will bring more benefit to the increasing number of COVID-19 patients in Israel and across the world. “Invented in 2017 and headquartered in Israel, Stereo Biotechs is a medical-stage business that emphasizes on the study and creation of new drug options focused on CBDs.